新鋭醫藥(06108.HK)上半年淨虧2137.8萬港元
格隆匯8月25日丨新鋭醫藥(06108.HK)發佈公吿,截至2022年6月30日止六個月,集團錄得收益約5929.3萬港元,同比減少約72.4%;上年同期公司擁有人應占溢利淨額約113.3萬港元,而該期間則轉為錄得公司擁有人應占虧損淨額約2137.8萬港元;基本及攤薄每股虧損1.28港仙。
公吿稱,期內總收益同比減少約72.4%。來自醫藥產品分銷及貿易的收益減少主要由於集團該產品(1.0g)的銷售減少。在2022年上半年,由於冠狀病毒病(Covid-19)病例再度出現,及受在多個地區進一步加強採用抗菌藥物分級分類管理政策的影響,集團的貿易活動及業務經營放緩。因此,期內對該產品(1.0g)的需求有所下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.